{
  "abstract": "Background\n\nOsimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy.Methods\n\nIn this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine-Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses.Results\n\nHFH occurred in 169 patients (2.9%) during a median on-treatment follow-up of 9.3 months, with 268 competing deaths. LASSO retained seven predictors. The apparent concordance index (C-index) was 0.731 (95% confidence interval, 0.691-0.771) and the optimism-corrected C-index 0.718. Observed incidence increased 10.2-fold across predicted-risk deciles (1.03-10.50%). Fine-Gray and Cox estimates closely matched the logistic model.Conclusions\n\nBaseline cardiovascular vulnerability stratifies HFH risk during osimertinib therapy. The nomogram, not externally validated, is best used as a screening aid to identify patients who may benefit from intensified cardiovascular monitoring.",
  "abstract_shown": true,
  "affiliations": [
    "Endowed Course of Advanced Medical Care Community Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi 501-1196, Gifu, Japan.",
    "Department of Pharmacy, Toyota Memorial Hospital, 1-1 Heiwa-cho, Toyota-shi 471-8513, Aichi, Japan.",
    "Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi 501-1196, Gifu, Japan.",
    "Department of Pharmacy, Kanagawa Prefectural Ashigarakami Hospital, 866-1 Matsudasoryo, Matsuda-machi, Ashigarakami-gun 258-0003, Kanagawa, Japan."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Tomoya Sugimoto"
    },
    {
      "affs": [
        2
      ],
      "name": "Yoshihiro Noguchi",
      "orcid": "0000-0002-9110-9604"
    },
    {
      "affs": [
        2
      ],
      "name": "Rikuto Masuda",
      "orcid": "0009-0007-5161-0035"
    },
    {
      "affs": [
        2
      ],
      "name": "Sorami Tani"
    },
    {
      "affs": [
        2,
        3
      ],
      "name": "Tomohiko Harada",
      "orcid": "0009-0009-4579-4565"
    },
    {
      "affs": [
        1
      ],
      "name": "Yukio Toyama",
      "orcid": "0009-0000-2630-8431"
    },
    {
      "affs": [
        0
      ],
      "name": "Mitsuru Saguchi"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Tomoaki Yoshimura",
      "orcid": "0009-0008-2486-8169"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/b8aq8te5ams88.bib",
  "cited_by": 0,
  "doi": "10.3390/curroncol33100586",
  "fulltext_url": "https://europepmc.org/articles/PMC13703609",
  "id": "b8aq8te5ams88",
  "issns": [
    "1198-0052",
    "1718-7729"
  ],
  "landing_url": "https://europepmc.org/article/MED/42930153",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7214727709",
  "pdf_url": "https://europepmc.org/articles/PMC13703609?pdf=render",
  "pmcid": "PMC13703609",
  "pmid": "42930153",
  "published": "2026-09-29",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/b8aq8te5ams88.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:01Z",
      "native_id": "MED:42930153",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42930153"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "Risk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy.",
  "title_text": "Risk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:22:01Z",
  "url": "https://research.draconitic.com/paper/b8aq8te5ams88",
  "venue": "Current oncology (Toronto, Ont.)",
  "versions": []
}